Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBottari, Gabriella
dc.contributor.authorSeverini, Flavia
dc.contributor.authorMarkowich, Anna Hermine
dc.contributor.authorLorenzetti, Giulia
dc.contributor.authorRuiz Rodriguez, Juan Carlos
dc.contributor.authorFerrer Roca, Ricard
dc.date.accessioned2022-09-16T07:31:20Z
dc.date.available2022-09-16T07:31:20Z
dc.date.issued2022-10
dc.identifier.citationBottari G, Severini F, Markowich AH, Lorenzetti G, Ruiz Rodriguez JC, Ferrer R, et al. Hemoadsorption for severe MIS-C in critically ill children, should we consider it as a therapeutic opportunity? Int J Artif Organs. 2022 Oct;45(10):871–877.
dc.identifier.issn1724-6040
dc.identifier.urihttp://hdl.handle.net/11351/8203
dc.descriptionCoronavirus; Multisystem inflammatory syndrome in children; Pediatric critical care
dc.description.abstractMultisystem inflammatory syndrome (MIS-C) is a new severe clinical condition that has emerged during the COVID-19 pandemic. MIS-C affects children and the young usually after a mild or asymptomatic COVID-19 infection. MIS-C has a high tropism for the cardiovascular system with need for inotropes and vasopressor support in 62% of cases. As of today a mortality from 1.5% to 1.9% related to MIS-C is reported. Hemoadsorption via the inflammatory mediator adsorber CytoSorb (CytoSorbents Europe, Berlin Germany) has been used as adjunctive therapy with the aim to restore the host response in septic shock and other hyper-inflammatory syndromes. We present the clinical experience of an adolescent boy with a refractory shock secondary to left ventricular dysfunction (LVD) in the context of MIS-C, treated with hemoadsorption, and continuous kidney replacement therapy (CKRT) in combination with immunomodulatory therapies. The therapeutic strategy resulted in hemodynamic and clinical stabilization as well as control of the hyperinflammatory response. Treatment appeared to be safe and feasible. Our findings are in line with previously published clinical cases on Cytosorb use in MIS-C showing the beneficial role of the hemoperfusion with Cytosorb in severe MIS-C to manage the cytokine storm. We provide an analysis and comparison of recent evidence on the use of hemoadsorption as an adjuvant therapy in critically ill children with severe forms of MIS-C, suggesting this blood purification strategy could be a therapeutic opportunity in severe LVD due to MIS-C, sparing the need for extracorporeal membrane oxygentation (ECMO) and other mechanical cardiocirculatory supports.
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.ispartofseriesThe International Journal of Artificial Organs;45(10)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia) - Complicacions
dc.subjectInflamació
dc.subjectCitocines
dc.subject.meshSystemic Inflammatory Response Syndrome
dc.subject.meshCoronavirus Infections
dc.subject.mesh/complications
dc.subject.meshCytokines
dc.titleHemoadsorption for severe MIS-C in critically ill children, should we consider it as a therapeutic opportunity?
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1177/03913988221111179
dc.subject.decssíndrome de respuesta inflamatoria sistémica
dc.subject.decsinfecciones por Coronavirus
dc.subject.decs/complicaciones
dc.subject.decscitocinas
dc.relation.publishversionhttps://doi.org/10.1177/03913988221111179
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Bottari G] Pediatric Intensive Care Unit, Pediatric Emergency Department, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. [Severini F, Markowich AH, Lorenzetti G] Department of Pediatrics, University of Rome Tor Vergata, Residency School of Pediatrics, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. [Ruiz Rodriguez JC, Ferrer R] Unitat de Cures Intensives, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Shock, Disfunció Orgànica i Ressuscitació, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid35822878
dc.identifier.wos000826167600001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record